- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Oncolytics Biotech Inc
+ Add to WatchlistONCY:US
2.4600 USD 0.2000 8.85%As of 20:10:00 ET on 06/19/2013.
Snapshot for Oncolytics Biotech Inc (ONCY)
| Open: | 2.2700 | Day's Range: | 2.2510 - 2.4600 | Volume: | 210,183 |
|---|---|---|---|---|---|
| Previous Close: | 2.2600 | 52wk Range: | 1.6000 - 4.9300 | 1-Yr Rtn: | -25.90% |
Key Statistics for ONCY
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (CAD) (ttm) | - |
| Est. EPS (CAD) (12/2013) | -0.3770 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 208.51 |
| Shares Outstanding (M) | 84.76 |
| 30 Day Average Volume | 261,894 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ONCY
Company Profile & Key Executives for ONCY
Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.
| Bradley G Thompson "Brad"Chairman/President/CEO | Kirk LookChief Financial Officer |
| Matthew C Coffey "Matt"Chief Operating Officer | Alan J TuchmanSenior VP:Clinical/Chief Medical Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ONCY News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page